Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Aclaris Therapeutics (ACRS) over the last 5 years, with Sep 2025 value amounting to $122.6 million.

  • Aclaris Therapeutics' Shares Outstanding (Diluted Average) rose 71.78% to $122.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.6 million, marking a year-over-year increase of 71.78%. This contributed to the annual value of $77.3 million for FY2024, which is 10.73% up from last year.
  • As of Q3 2025, Aclaris Therapeutics' Shares Outstanding (Diluted Average) stood at $122.6 million, which was up 0.03% from $122.6 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Shares Outstanding (Diluted Average) registered a high of $122.6 million during Q3 2025, and its lowest value of $50.3 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $85.2 million, with a median of $71.3 million in 2024.
  • Data for Aclaris Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY soared of 72.20% (in 2025) over the last 5 years.
  • Aclaris Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $56.7 million in 2021, then climbed by 14.95% to $65.2 million in 2022, then increased by 7.05% to $69.8 million in 2023, then climbed by 10.73% to $77.3 million in 2024, then skyrocketed by 71.78% to $122.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $122.6 million for Q3 2025, versus $122.6 million for Q2 2025 and $122.4 million for Q1 2025.